| |
If your pharma teams are still overwhelmed with the volume, velocity, and variety of data and missing opportunities to enable reliable insights and answer critical business questions, read this insight brief to learn more. 
|
|
| By Annalee Armstrong The world’s pharmaceutical companies are set to invest $302 billion in R&D by 2028—but what will they get in return? Fierce Biotech explores the 10 therapies with the highest potential value. |
|
|
|
| Philadelphia, PA |  |
|
|
By Angus Liu Just as Novartis’ C-suite appeared to have stabilized amid a major overhaul of the company, the Swiss pharma is losing its international markets leader and getting rid of its chief commercial officer title. |
By Fraiser Kansteiner Friday, the U.S. Federal Trade Commission (FTC) said it reached a proposed consent order with Amgen to address “the potential competitive harm” that could result from the merger deal. Now, Amgen is free to go forward with its $28 billion buyout. |
By Max Bayer Japanese pharma Otsuka is acquiring Mindset Pharma for $59 million, adding a suite of preclinical psychedelics. The larger company is looking to build on its portfolio of Lundbeck-partnered antipsychotics that each raked in hundreds of millions of dollars last quarter. |
|
Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today. 
|
|
By James Waldron Sana Biotechnology isn't revealing how many employees have been affected by its latest round of layoffs, only confirming that the CAR-T-focused company has sought further “operational efficiencies.” |
By Fraiser Kansteiner The FDA handed the company a complete response letter for its Ultomiris application in neuromyelitis optica spectrum disorder, a rare autoimmune disease affecting the central nervous system. |
By Gabrielle Masson The latest financing will in part go toward VGA039, an early-stage mAB being developed by Star's offshoot Vega to treat von Willebrand disease. |
By Conor Hale Jacob Thaysen will make the jump after serving as Agilent Technologies' president of life sciences and applied markets. He will take the top job at Illumina Sept. 25. |
By Nick Paul Taylor Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics. |
By Angus Liu GSK is laying out more than 250 million euros ($273 million) to bolster vaccine manufacturing with a new facility in Wavre, Belgium. The unit will handle freeze-dried vaccines, including Shingrix and Arexvy. |
By Helen Floersh The company's VivoVec platform has generated in vivo chimeric antigen receptor T cells, or CAR-T cells, in nonhuman primates, according to new data presented by the company Sept. 1 during the annual CAR-TCR Summit in Boston. The CAR-Ts also appeared to have activity against target cells and continued proliferating for more than a month in one of the animals. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Tuesday, September 19, 2023 | 11am ET / 8am PT In this webinar, discover the rise of omnichannel engagement in life sciences and how the blend of in-person and digital channels is reshaping the industry. Learn from the IQVIA Brand Impact™ survey insights, understand the challenges in strategy execution, and explore how to achieve excellence in customer engagement. Register now. 
|
|
Whitepaper Access this insightful whitepaper to explore the role collaboration platform technology can play in helping address current industry challenges and to generate business value. Sponsored by: Zoom |
Whitepaper Discover five creative and innovative ways to reimagine your legacy biopharma campus and unlock value. Sponsored by: JLL |
Whitepaper Download now to gain access to real-world case studies that highlight the innovative tools and strategies leading companies have implemented to improve processes and fully realize efficiencies and reductions in time to treatment. Sponsored by: Appian |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Learn how to close the knowledge gap for cancer patients by increasing awareness of important aspects of their condition, treatment options and support resources. Sponsored by: Phreesia Life Sciences |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Unravel the intricacies of Cell Line Development in biotherapeutics production with our latest eBook chapter. Sponsored By: Danaher Life Sciences |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
